Eden Research (EDEN) AI Stock Analysis

• Market Cap: £17.60M
• Dividend Yield: N/A
• Average Volume (3M): 188.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: 34.79%
• EPS Growth: 78.31%
• Country: UK
• Employees: 23
• Sector: Basic Materials
• Sector Strength: 60
• Industry: Agricultural Inputs
• EPS (TTM): >-0.01
• Shares Outstanding: 533,352,540
• 10 Day Avg. Volume: 142,442
• 30 Day Avg. Volume: 188,368
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £3.50
• Price Target Upside: 6.06% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: 3.50p ▲(6.06% Upside)

Eden Research's stock score is primarily impacted by its financial challenges, with profitability and cash flow issues posing significant risks. Technical indicators suggest weak momentum, although oversold conditions may offer a rebound opportunity. Positive corporate events and strategic advancements provide some optimism for future growth.

Eden Research Business Overview & Revenue Model

Company Description

Eden Research (EDEN) is a pioneering biotechnology company focused on developing sustainable solutions for agriculture and horticulture. The company specializes in providing innovative biopesticides and biofungicides derived from natural plant extracts, aimed at improving crop yield and reducing chemical pesticide usage. Eden Research operates within the agricultural sector, targeting both farmers and agricultural businesses with its environmentally friendly products designed to meet the growing demand for sustainable farming practices.

How the Company Makes Money

Eden Research generates revenue primarily through the sale of its biopesticide and biofungicide products to agricultural producers and distributors. The company's revenue model includes direct product sales, licensing agreements, and collaborations with agricultural firms to develop new products. Key revenue streams are supplemented by strategic partnerships with industry leaders that enhance product distribution and market reach. Additionally, Eden may generate income through research and development grants or funding from agricultural innovation initiatives aimed at promoting sustainable farming solutions.

Eden Research Financial Statement Overview

Summary

Eden Research shows revenue growth potential, but faces profitability challenges, as indicated by negative EBIT and net income. While the balance sheet is stable, cash flow issues pose sustainability risks.

Income Statement

Eden Research shows a positive trend in revenue growth, with an increase from previous years, indicating potential market expansion. However, the company struggles with profitability, as evidenced by negative EBIT and net income figures. The gross profit margin is moderate, but net profit margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

The company maintains a solid equity position with a high equity ratio, indicating financial stability. However, the debt-to-equity ratio, while low, highlights limited leverage which could constrain growth. The declining stockholders' equity over the years suggests potential risk if losses persist.

Cash Flow

Eden Research faces significant cash flow challenges, with consistently negative free cash flow and operating cash flow figures. The company has not demonstrated consistent improvement in cash flow ratios, which could impact its ability to fund operations without external financing.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.30M	3.19M	1.83M	1.23M	1.37M
Gross Profit	1.87M	1.77M	207.14K	28.32K	9.63K
EBITDA	-1.59M	-6.24M	-1.83M	-2.72M	-1.87M
Net Income	-1.91M	-6.49M	-2.24M	-2.79M	-2.27M
Balance Sheet
Total Assets	15.41M	16.59M	12.91M	15.03M	16.92M
Cash, Cash Equivalents and Short-Term Investments	3.67M	7.41M	1.99M	3.83M	7.29M
Total Debt	168.73K	229.77K	355.32K	398.35K	415.25K
Total Liabilities	3.57M	3.05M	2.17M	2.20M	2.00M
Stockholders Equity	11.82M	13.52M	10.72M	12.80M	14.91M
Cash Flow
Free Cash Flow	-3.60M	-3.41M	-1.74M	-3.34M	-2.92M
Operating Cash Flow	-1.01M	-1.70M	-683.10K	-1.62M	-1.02M
Investing Cash Flow	-2.48M	-1.72M	-1.05M	-1.73M	-1.90M
Financing Cash Flow	-155.53K	8.90M	-150.35K	-90.39K	9.71M

Eden Research Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:EDEN, the sentiment is Negative. The current price of 3.3 is below the 20-day moving average (MA) of 3.34, below the 50-day MA of 3.56, and below the 200-day MA of 3.52, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 26.55 is Positive, neither overbought nor oversold. The STOCH value of 44.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:EDEN.

Eden Research Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GDP	78 Outperform	£12.38M	2.88	23.30%	―	10.56%	99.25%
GEMD	69 Neutral	£9.72M	4.34	2.04%	―	6.94%	―
POW	58 Neutral	£16.47M	5.17	18.19%	―	―	―
CRPR	57 Neutral	£24.84M	―	-22.92%	―	-3.52%	-31.82%
Sector *	56 Neutral	£2.53B	6.27	-0.23%	46.00%	10.12%	5.01%
ITX	50 Neutral	£17.19M	―	-17.98%	―	-19.70%	-15.81%
EDEN	48 Neutral	£17.60M	―	-15.05%	―	34.79%	78.31%

Eden Research Corporate Events

Eden Research Secures Shareholder Approval at AGM

Eden Research plc announced that all resolutions proposed at its Annual General Meeting were passed, indicating strong shareholder support. The approval of these resolutions, including the reappointment of auditors and the re-election of directors, reinforces the company’s strategic direction and operational stability.

Eden Research Reports Strong Progress and Future Prospects in Sustainable Biopesticides

Eden Research plc has reported significant progress in its operations, with a 34% increase in revenue year-on-year, driven by key regulatory milestones and product development advancements. The company has achieved regulatory approvals for its products in major markets such as California, Spain, and Mexico, opening substantial commercial opportunities. Eden’s pipeline remains robust with new products under development, including a bioinsecticide targeting key pests. The company is optimistic about its future prospects, supported by increasing demand for biopesticides and regulatory support for sustainable farming practices.

Eden Research Partners with Royal Holloway to Expand Seed Treatment Development

Eden Research has announced a strategic partnership with Royal Holloway, University of London, under Innovate UK’s Knowledge Transfer Partnership scheme. This collaboration aims to expand Eden’s seed treatment product to include new cereal and vegetable seeds, leveraging academic expertise and facilities to enhance product development. The partnership is expected to provide significant growth opportunities for Eden by enabling the company to enter larger markets with its sustainable seed treatment solutions, which are currently used for maize seeds and are under review for EU-wide authorization.

Eden Research Releases 2024 Annual Report and Announces AGM

Eden Research plc has published its Annual Report and Accounts for the year ending December 31, 2024, and announced the Notice of its Annual General Meeting (AGM), which will be held on June 18, 2025, in London. This announcement marks a significant step in maintaining transparency with shareholders and stakeholders, reflecting Eden’s commitment to sustainable practices in the biopesticide industry.

Eden Research Expands Mevalone® Use in California Grape Market

Eden Research plc has announced the approval of its fungicide Mevalone® for controlling powdery mildew in Californian grapes, expanding its use beyond its current approval for Botrytis cinerea. This regulatory approval enhances the product’s versatility for growers, particularly in California, which is a significant market for grape production. Despite the potential for increased market share, Eden does not anticipate immediate changes in revenue expectations. The approval underscores Eden’s commitment to sustainable agriculture and provides Californian grape growers with an effective, residue-free alternative to conventional fungicides.